IL296579A - Antibody against ccl24 for use in a treatment method - Google Patents

Antibody against ccl24 for use in a treatment method

Info

Publication number
IL296579A
IL296579A IL296579A IL29657922A IL296579A IL 296579 A IL296579 A IL 296579A IL 296579 A IL296579 A IL 296579A IL 29657922 A IL29657922 A IL 29657922A IL 296579 A IL296579 A IL 296579A
Authority
IL
Israel
Prior art keywords
ccl24
monoclonal antibody
pharmaceutical composition
administration
antibody
Prior art date
Application number
IL296579A
Other languages
English (en)
Hebrew (he)
Original Assignee
Chemomab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemomab Ltd filed Critical Chemomab Ltd
Publication of IL296579A publication Critical patent/IL296579A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
IL296579A 2020-04-22 2021-04-20 Antibody against ccl24 for use in a treatment method IL296579A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063013793P 2020-04-22 2020-04-22
PCT/IL2021/050447 WO2021214759A1 (en) 2020-04-22 2021-04-20 Method of treatment using anti-ccl24 antibody

Publications (1)

Publication Number Publication Date
IL296579A true IL296579A (en) 2022-11-01

Family

ID=75787181

Family Applications (1)

Application Number Title Priority Date Filing Date
IL296579A IL296579A (en) 2020-04-22 2021-04-20 Antibody against ccl24 for use in a treatment method

Country Status (9)

Country Link
US (1) US20230235037A1 (enExample)
EP (1) EP4139352A1 (enExample)
JP (1) JP2023522907A (enExample)
KR (1) KR20230013037A (enExample)
CN (1) CN115427445A (enExample)
AU (1) AU2021259682A1 (enExample)
CA (1) CA3172627A1 (enExample)
IL (1) IL296579A (enExample)
WO (1) WO2021214759A1 (enExample)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121022A (en) * 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US20040191243A1 (en) * 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
EP1706424B1 (en) * 2004-01-12 2009-07-22 Applied Molecular Evolution, Inc. Fc region variants
US9067989B2 (en) 2009-01-28 2015-06-30 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Eotaxin-2 (CCL24) inhibitors in inflammatory, autoimmune, and cardiovascular disorders
EP2490026A4 (en) * 2009-10-16 2013-08-21 Mochida Pharm Co Ltd MARKER ASSOCIATED WITH NON ALCOHOLIC STÉATOHÉPATITE
BR112012022223B1 (pt) * 2010-03-01 2022-08-09 Cytodyn Inc Formulação de proteína concentrada, uso e método de preparação da mesma
DK3114139T3 (da) 2014-03-04 2022-09-12 Chemomab Ltd Anti eotaxin-2 antistoffer, der genkender supplerende ccr3-bindende chemokiner
CR20170060A (es) * 2014-08-19 2017-04-18 Merck Sharp & Dohme Anticuerpos anti tigit
WO2016040882A1 (en) * 2014-09-13 2016-03-17 Novartis Ag Combination therapies of egfr inhibitors
US20180008707A1 (en) * 2015-02-13 2018-01-11 Sanofi Stable liquid formulation for monoclonal antibodies
JP7155009B2 (ja) * 2016-03-25 2022-10-18 ビステラ， インコーポレイテッド デングウイルスに対する抗体分子の製剤
EP4652926A3 (en) * 2016-10-12 2026-03-18 Bioverativ USA Inc. Anti-c1s antibodies and methods of use thereof
IL251024A0 (en) 2017-03-08 2017-06-29 Chemomab Ltd Antibodies against eutaxin 2 for use in the treatment of liver diseases
CN107198773A (zh) * 2017-06-08 2017-09-26 上海药明生物技术有限公司 重组抗pd‑l1全人单克隆抗体的液体制剂
EP3660155A4 (en) * 2017-07-27 2021-04-07 Daiichi Sankyo Company, Limited ANTI-CD147 ANTIBODY
CN109745559A (zh) * 2017-11-01 2019-05-14 三生国健药业（上海）股份有限公司 抗人il-17a的单克隆抗体的液体制剂
CN110354073B (zh) * 2018-04-09 2021-10-01 鲁南制药集团股份有限公司 一种免疫抑制剂单克隆抗体的液体制剂

Also Published As

Publication number Publication date
JP2023522907A (ja) 2023-06-01
EP4139352A1 (en) 2023-03-01
WO2021214759A1 (en) 2021-10-28
KR20230013037A (ko) 2023-01-26
CA3172627A1 (en) 2021-10-28
US20230235037A1 (en) 2023-07-27
AU2021259682A1 (en) 2022-10-20
CN115427445A (zh) 2022-12-02

Similar Documents

Publication Publication Date Title
CN109789194B (zh) 用angptl8抑制剂和angptl3抑制剂治疗高脂血症的方法
IL296519A (en) Anti-igf-1 receptor humanized antibody
IL260931B1 (en) Methods for treating or preventing atherosclerosis by administering an inhibitor of angptl3
IL272321B2 (en) Methods and compositions for treatment of amyloid deposition diseases
NZ581834A (en) Humanized antibodies to amyloid beta
IL261006A (en) Method and preparation for the treatment of cancer, killing of metastatic cancer cells and prevention of cancer metastases using an antibody to advanced glycation end products
IL263630B2 (en) Stable liquid pharmaceutical preparation
IL270894B (en) Human antibodies to bet v 1 and methods of use thereof
IL272361B1 (en) Antibodies that bind active alpha-synuclein
IL264636B (en) High concentration antibody formulations
CN106103479B (zh) 识别其它ccr3-结合趋化因子的抗嗜酸粒细胞趋化因子-2抗体
IL296214A (en) Methods for treating atopic dermatitis by administering an il-4r antagonist
IL295122A (en) Long-term gm-csf and methods of use
IL285171B1 (en) Treatment of skin lesions and pruritus in prurigo nodularis patients
IL298370A (en) Methods of treating iga nephropathy with an april binding antibody
IL278978B1 (en) Preparations and methods for treating psoriasis
IL300059A (en) Anti-Abata antibodies
IL323031A (en) Use of anti-CEACAM5 immunoconjugates for the treatment of neuroendocrine tumors expressing CEACAM5
IL292029A (en) Humanized antibodies against chemokin like receptor 1 and their therapeutic uses
IL302383A (en) Method of safe administration of anti-tau antibody
IL323157A (en) Antitumor combinations containing conjugates of anti-ceacam5 antibodies, anti-vegfr-2 antibodies, and anti-pd1/pd-l1 antibodies
IL297640A (en) Methods and combinations for cancer treatment using immune checkpoint inhibitor antibodies
IL298155A (en) Methods of treating cancer using a combination of anti-cd30 antibody-drug conjugates
IL302386A (en) Methods of reducing tau in human subjects
JP7798763B2 (ja) Ｃ５関連疾患の治療または予防のための投与レジメン